Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Seqirus’ Pandemic Flu Vaccine Approved: Next Generation Technology Strengthens Preparedness

    By Global Biodefense StaffFebruary 3, 2020
    Influenza Transmission Spikes During Social Gatherings
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.

    The vaccine was developed with support from the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and will be produced at a facility in Holly Springs, North Carolina to help ensure the vaccine will be available to the American people when they need it most.

    AUDENZ  uses two leading-edge technologies – an antigen-sparing adjuvant and cell-based vaccine technology – that represent a game-changing advance in the state of pandemic influenza preparedness.

    As the recent outbreak of a novel coronavirus reminds us, people travel around the world every day and the viruses they may carry do not respect borders. Just over a decade ago, the H1N1 pandemic spread throughout the globe in just a few weeks. During the 2009 pandemic, pregnant women, young children, and other vulnerable populations suffered particularly high rates of infection. A decade before that, the threat of an H5N1 influenza pandemic emerged, with periodic transmission of H5N1 from birds to people, and the threat remains real. Now, we have a licensed cell-based and adjuvanted vaccine that can be manufactured in the U.S. to protect children over 6 months of age, older adults, and other medically vulnerable people. We are better prepared to protect people during an H5N1 pandemic.

    Rick A. Bright, Ph.D., BARDA Director and Deputy Assistant Secretary for Preparedness and Response

    Most influenza vaccines are manufactured using embryonated chicken eggs, which makes the production of pandemic influenza vaccines vulnerable to disruptions in the egg supply and variations in the ways different strains of the virus grow in an egg. Like many agricultural products, egg production is seasonal and the supply of eggs wanes just as the demand for a pandemic influenza vaccine could increase. Although BARDA worked with egg producers to overcome this challenge, responding to a pandemic requires large-scale continuous manufacturing, and egg-based processes have limitations. We would need to use an array of vaccine technologies to produce enough vaccine domestically as quickly as possible.

    AUDENZ uses cell-based vaccine technology and an adjuvant, which boosts the body’s immune response and makes the vaccine more effective overall. In the early days of a pandemic, the amount of vaccine that can be manufactured is limited by the amount of antigen – the part of a vaccine that arms the immune system – that can be produced. However, the adjuvant used in AUDENZ  reduces the amount of antigen needed for the vaccine. By using this antigen-sparing technology, more doses of AUDENZ can be made from the same amount of antigen while maintaining the safety and effectiveness of the vaccine. Ultimately, that means more vaccine is available in a given time period.

    AUDENZ will use the same adjuvant production facility as FLUAD®, a seasonal influenza vaccine produced by Seqirus in North Carolina. In a pandemic, that facility would ramp up and begin supporting AUDENZ. By leveraging the existing domestic manufacturing infrastructure in a facility that is used to make a seasonal product, Seqirus is uniquely positioned to manufacture cell-based vaccines on a pandemic scale as a result of its public-private partnership with the BARDA.

    ASPR BARDA Drug Development Editor Pick H5N1 HHS Influenza Magazine Edition 6 Feb 2020 Pandemic Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBARDA Seeks Input from Suppliers on Potential SARS-CoV-2 Medical Countermeasures
    Next Article Technology Accelerator Challenge: Non-Invasive, Handheld, Digital Diagnostic Device

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.